Cardio-Onco-Hematology in Clinical Practice. Position Paper and Recommendations

Rev Esp Cardiol (Engl Ed). 2017 Jun;70(6):474-486. doi: 10.1016/j.rec.2016.12.041. Epub 2017 Mar 18.
[Article in English, Spanish]


Improvements in early detection and treatment have markedly reduced cancer-related mortality. However survival not only depends on effectively cure cancer, but prevention, diagnosis and treatment of cancer-related complications is also needed. Cardiovascular toxicity is a widespread problem across many classes of therapeutic schemes, however scientific evidence in the management of cardiovascular complications of onco-hematological patients is scarce, as these patients have been systematically excluded from clinical trials and current recommendations are based on expert consensus. Multidisciplinary teams are mandatory to decrease morbidity and mortality from both cardiotoxicity and cancer itself. An excessive concern for the occurrence of cardiovascular toxicity, can avoid potentially curative therapies, while underestimating this risk, increases long-term mortality of cancer survivors. The objective of this consensus document, developed in collaboration of the Spanish Society of Cardiology, the Spanish Society of Medical Oncology, the Spanish Society of Radiation Oncology and the Spanish Society of Hematology, is to update the necessary concepts and expertise on cardio-onco-hematology that enable its application in daily clinical practice and to promote the development of local multidisciplinary teams, to improve the cardiovascular health of patients with cancer.

Keywords: Cardio-Oncology; Cardio-Oncología; Cardiotoxicidad; Cardiotoxicity; Chemotherapy; Quimioterapia; Radioterapia; Radiotherapy.

Publication types

  • Review

MeSH terms

  • Cardiology / standards*
  • Cardiovascular Diseases / prevention & control*
  • Consensus*
  • Hematology / standards*
  • Humans
  • Medical Oncology / standards*
  • Neoplasms / prevention & control*
  • Primary Prevention / standards*